Following major regulators in the U.S., China and Japan, the European Commission has given Takeda the go-ahead for its $62 billion acquisition of Shire—on one condition that Takeda is willing to fulfill.
As expected, the latest approval is dependent on Takeda selling off Shire’s investigational inflammatory bowel disease (IBD) drug SHP647. EU regulators previously shared concerns over the drug’s potential overlap with Takeda’s blockbuster Entyvio, and in response, Takeda has committed to selling it.
Calling SHP647 “an exciting pipeline compound,” Takeda said it expects the drug “to attract interest from a number of potential buyers.”
Both Entyvio and SHP647 are anti-integrin monoclonal antibodies intended for IBD. Because they’re expected to compete closely in the same market, EU antitrust officials were worried that innovation would be stymied if both drugs were held in one company’s hands.
Takeda actually already intended to end development of the Shire drug after the merger, the agency noted in a Tuesday announcement. “It would have … prevented a product from reaching the market that could compete with Entyvio and reduce prices for this type of biologic treatment,” it said.
Now that the Japanese pharma has willingly agreed to divest the product, it “will preserve innovation in this market and, importantly, increase the choice of treatments for patients,” Commissioner Margrethe Vestager, responsible for competition policy, said.
As the “cornerstone” of Takeda’s gastrointestinal portfolio, Entyvio has been a major growth driver lately. Its sales increased by more than 40% in the previous fiscal year, to $1.84 billion, and it’s also on track to deliver another 30%-plus jump this year. In comparison, SHP647 could be a much smaller asset, as GlobalData experts have projected sales of less than $100 million by 2023.
SHP647 might not be the only drug Takeda is selling to enable the gigantic Shire deal. Rumor has it that the company is scouting buyers for eye drop Xiidra and hypoparathyroidism therapy Natpara, which could drum up about $5 billion in total. Some European OTC assets potentially worth about $1 billion are also reportedly on the for-sale list.
While winning European clearance represents the transaction’s final regulatory green light, Takeda has yet another hurdle to overcome to seal the deal: approval from its shareholders.
Despite management’s repeated emphasis on the importance of growing Takeda’s pipeline and global footprint, a group of rebel investors, led by some members of Takeda’s founding family, are still making every effort to fight the acquisition. These dissidents control about 1% of the company’s stock, but they’re looking to persuade 25% of Takeda shareholders to oppose the deal ahead of the planned vote on Dec. 5, according to the Financial Times.
CEO Christophe Weber, though, appears confident that he can win two-thirds of shareholder support to issue new shares to finance the transaction.
“After several months of constructive dialogue, we are optimistic that our shareholders recognize the significant long-term value creation potential of this powerful combination,” he said in a statement.
By Angus Liu
Source: Fierce Pharma
Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.
Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.
Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”
